Pancreas Cancer Clinical Trial
Official title:
Long-term Benefit of Elderly Pancreatic Ductal Adenocarcinoma Patients After Pancreaticoduodenectomy
Verified date | September 2018 |
Source | The First Affiliated Hospital of Dalian Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
We used the SEER database to analyze the data of patients with PDAC. The database includes
patients of 18 registries in the USA from 1973-2013All the malignant cases were followed-up
annually to determine vital status.
The aim of Our study is to make clearly the long-term survival of younger (age <80 years) and
elderly (age ≥80 years) pancreatic cancer patients underwent PD. Sec-ond, find out the risk
factors of poor prognosis in elderly patients.
Status | Completed |
Enrollment | 5910 |
Est. completion date | September 1, 2018 |
Est. primary completion date | December 13, 2013 |
Accepts healthy volunteers | |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Patients with pancreatic ductal adenocarcinoma,treatment by pancreaticoduodenectomy.Only cases that underwent PD and microscopically confirmed were included. Exclusion Criteria: - Patients with no survival data. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital of Dalian Medical University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | median OS | The median overall survival of all patients | to 2013 Dec. 31 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05435053 -
Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Recruiting |
NCT06065891 -
Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05048524 -
Peri-operative SLOG for Localized Pancreatic Cancer
|
Phase 2 | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Recruiting |
NCT05679674 -
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
|
N/A | |
Recruiting |
NCT05501379 -
Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker
|
||
Recruiting |
NCT04851106 -
Evaluation of Endoscopic Ultrasound Shear Wave Elastography (EUS-SWE) for the Diagnosis of Pancreatic Adenocarcinoma.
|
||
Enrolling by invitation |
NCT04466189 -
Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy
|
||
Not yet recruiting |
NCT06036563 -
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
|
||
Terminated |
NCT01313416 -
Gemcitabine and CT-011 for Resected Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT01411072 -
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer
|
N/A | |
Active, not recruiting |
NCT01448668 -
Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)
|
N/A | |
Completed |
NCT01155882 -
Registry Study - Whipple at the Splenic Artery
|
||
Recruiting |
NCT04970056 -
Pancreatic Cancer Early Detection Consortium
|
||
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03682744 -
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
|
Phase 1 |